PFE 全部观点

已加载 11 条观点条目,其中 0 条方向发生变化

在已加载记录中筛选
《3 Stocks I Own - Research Platform Overview!》
$PFE看涨
AI 摘要 · 辉瑞是占组合 4% 的仓位,其传统业务和规模提供了安全性,应能随时间创造价值;近期盈利良好,回购也已恢复。利润可能扭转暴跌背后的下滑,留下价值级别的个位数市盈率,长期看 PFE 预计表现良好。若 2028 年 EPS 达到 10 美元,或达到该目标的一半,按 12 倍市盈率计算将是相当不错的回报;这是买入实际盈利,而非过去的预期。

辉瑞,我们已经开始在其中建立一个投资仓位。它占投资组合的4%,我认为它的传统业务、核心环节、银行等等,以及业务的规模,都存在安全性,应该会随着时间推移创造价值。始终存在一种可能:导致该股暴跌的利润下滑出现逆转,使其跌至一个价值水平、个位数市盈率。

随着时间推移,预计它会有不错的表现。他们已经恢复了回购操作,最近的盈利也不错。如果他们能实现自己的目标,甚至只实现一半,比如说2028年每股收益达到10美元,乘以12,那就是相当不错的回报。

你买的是实际盈利,不是导致该股崩盘的过去预期,而是实际盈利。

Pfizer, we have started opening an investment center in it. It represents 4% of the portfolio, and I believe there is security in its traditional business, in the core links , the banks, everything, and the scale of the business there that should generate value over time.

There is always the possibility of a reversal of the profits that led to the stock's collapse, bringing it down to a value level and single-digit price-to-earnings ratios . Over time, it is expected to perform well.

They have returned to buyback operations , and recent earnings have been good. And if they manage to achieve their goal, or even half of it, let's say they reach $10 earnings per share in 2028 multiplied by 12, that's a really good return.

You're buying actual earnings , not past expectations that caused the stock to crash, but actual earnings.

他说在等
Pfizer 在2028年实现每股收益10美元,或达到该目标的一半
2028年每股收益10美元,或该目标的一半
2028年2028年财报
支持预期中的良好回报
Schwab Network发布 2026-11-02
《Ted Weisberg on META Value Opportunity in AI, Going Long on Energy & Airlines》
$PFE看涨
AI 摘要 · 辉瑞是一只值得继续持有的好股票:公司实力强、资产负债表良好,其丰厚股息让投资者在等待期间获得回报。它历来表现平淡,在价值与科技的对比中远远落后于近期表现优异的大型制药板块。

而辉瑞,你知道,一直很沉闷。制药公司,大型制药公司,最近做得很好。再一次,价值与科技的对比,我认为辉瑞远远落后于这个群体。它支付高额股息,所以你在等待时能拿到钱。强大的公司,良好的资产负债表。我认为这是一只值得保留的好股票。

And Pfizer, you know, was forever dull. Pharmaceutical companies, big pharmaceutical companies, have been doing great work recently. Once again, value versus tech, and I think Pfizer is far behind this group.

It pays big dividends, so you're getting money while you wait. Strong company, good balance sheet. I think this is a good stock to keep.

Brian Shannon发布 2026-10-20
《Brian Shannon on TraderTV Live 10/20/26》
$PFE看涨
AI 摘要 · PFE 突破了长期盘整,并在周线图上突破了 2022 年的锚点水平,看起来正朝 32 附近迈进,即其 2021 年高点的锚点。他在突破后买入,部分原因是 7% 的股息,目前只持有小仓位。

Pfizer的涨幅比我预期的要好。那其实是上周二,哦,才那时候吗?好吧,不错,是的。是的,Brian预测了Pfizer的突破。

Pfizer has risen better than I expected. That was actually last Tuesday and oh, was it only then? Okay, nice, yes. Yes, Brian predicted that Pfizer breakthrough.

你在Pfizer身上看到了什么?是什么让你兴奋?你进场了吗?你怎么看Pfizer?是什么促使你投资这只股票的?

What did you see in Pfizer? What made you excited? Did you get in? what do you think of Pfizer? What led you to invest in this stock?

T3 Live发布 2026-10-18
《Actionable Swing Trade Ideas for Oct 19 – 23, 2026 | Market Update》
$PFE看涨
AI 摘要 · 他持有 Pfizer,制药商和生物科技类股整体看起来还可以,这是他持有该仓位的依据;未给出针对该股本身的具体理由。

我持有 Pfizer,如你所见,很多那个……叫什么来着?生物科技、制药公司看起来都还行。

I'm in the Pfizer and as you can see a lot of the the What do you call it? The biotech, the drug makers look okay.

Ale's World of Stocks发布 2026-10-16
《Pfizer Stock: How AI & $80 Billion Acquisition Spree Could Spark a Monster Rebound! 🚨》
$PFE看涨
AI 摘要 · PFE 是最佳被低估长期机会之一:股息率超过6%,派息率低于60%,并有成本削减;尽管营收与利润超预期,其市盈率仍比行业平均水平低50%以上,低于疫情前及十年前水平。800亿美元收购和 AI 应能抵消疫情相关销售下滑并实现超越。

今天,我们将深入了解市场上派息规模最大的大型公司之一:辉瑞(股票代码为 PFE)。乍看之下,人们可能会以为,收益型投资者会被其巨额股息派发、持续增长股息的过往记录,乃至其最近极低的估值所打动。然而,目前华尔街似乎并不愿意碰这只股票。

Today, we will take a closer look at one of the biggest dividend-paying major companies in the market: Pfizer (its stock ticker symbol is PFE). At first glance, one might expect income investors to be impressed by its huge dividend payouts, its track record of consistently growing them, and even its very recent extremely low valuation .

However , it seems that Wall Street does not want to deal with this stock at the moment.

Brian Shannon发布 2026-10-13
《Brian Shannon on TraderTV Live 10/13/26》
$PFE看涨
AI 摘要 · PFE 收益率为 7%,可能是一项长期股息投资;其周线图仍在 2022 年高点面前挣扎,但这是一个合理的长期基础,而月线图也不像过去那样糟糕。它开始看起来不错并引起兴趣;如果底部真的出现,7% 的收益率就在那里。

哦,你知道吗?我之前听你谈到股息。也许辉瑞是人们想投资的股票之一。好吧。它的股息是7%,如果你看这张周线图,你会看到我们正在与2022年高点的一个锚点位置较劲,这对长期来说是个不错的基础,而且股息是7%。

所以也许这是一笔股息投资。我自己不会这么做,你知道,那不是我的风格,但这是我考虑过的一只股票。

Oh, you know what? And I heard you talking about dividends earlier. Perhaps Pfizer is one of the stocks people want to invest in. Okay. That is a dividend of 7%, and if you look at this weekly chart, you see that we are struggling with an anchor point from the 2022 peak, and that is a nice basis for the long term, and it is 7%.

So maybe that is a dividend investment. I would n't do it myself, you know, that's not my thing, but it's one that crossed my mind .

Ale's World of Stocks发布 2026-09-27
《Saudi Arabia is Secretly Loading Up on THESE 5 Stocks! 🚨》
$PFE看涨
AI 摘要 · PFE 估值较低且股息率超过 6%;尽管过去表现不佳,市场当前仍忽视了 PFE。

比如Pfizer,它不仅价格和估值更便宜,而且股息收益率超过6%,而Eli Lilly的股息收益率不到1%。我明白Pfizer的表现非常糟糕,当然。这是悲观者可能会提出的论点,但我实际上认为市场目前在很大程度上忽视了这一点,而我对Eli Lilly则不能这么说。

like Pfizer, for example, which is not only cheaper in price and valuation , but also generates more than 6% as a dividend yield, while Eli Lilly generates less than 1%. I understand that Pfizer's performance was very bad, certainly.

This is the argument that pessimists might make , but I actually think the market is largely overlooking it right now, while I can't say the same about Eli Lilly.

Parkev Tatevosian, CFA发布 2026-09-17
《Is Pfizer an Excellent Dividend Stock to Buy? | PFE Stock Analysis》
$PFE看涨
AI 摘要 · 辉瑞值得买入;现金流折现模型给出的合理价值为50美元,意味着较当前水平有显著上行空间。

辉瑞的管理层已经在运用人工智能来帮助加速药物研发,这是我在人工智能领域看到的最大看涨机会之一,即它能为全人类带来的总机会价值。

Pfizer's management team is already incorporating artificial intelligence to help accelerate drug discovery, which is one of the biggest bullish opportunities that I see with artificial intelligence in the total opportunity value it can add to humanity worldwide.

他们也在利用人工智能来帮助优化生产良率,并提升其商业销售团队的有效性,但我认为对于这些制药公司来说,更大的机会在于药物研发。

They're also using artificial intelligence to help optimize manufacturing yields and enhance the effectiveness of its commercial sales force, but I think the bigger opportunity is in drug discovery with these pharmaceutical companies.

Ale's World of Stocks发布 2026-09-12
《Every Stock I'm Buying in September 2026 (Huge Opportunities)》
$PFE看涨
AI 摘要 · PFE 在估值与股息方面是最佳的生物科技标的,被视为稳健的长期持有品种。

辉瑞,在我看来,就整体估值和股息而言,辉瑞目前是最好的生物科技公司。所以,是的,我们的仓位有点重,但我认为这没关系。它只占投资组合的4%左右。

Um Fizer, you know, in my opinion, Fizer is like the best like biotech in terms of an overall package valuation dividend wise right now. So, yeah, we're we are a little heavy on it, but I think that's okay. It's only around 4% of the portfolio.

所以,再说辉瑞,就估值和股息而言,它整体上是最好的生物科技公司。我认为它是一只稳健的生物科技、制药标的,随便你怎么称呼它。

So, Fizer, again, it's like the overall best biotech in terms of valuation and dividend. I think it's a solid biotech uh pharmaceutical play, whatever you want to call it,

Schwab Network发布 2026-09-02
《Hayes: "950 Billion Reasons" to Buy Bonds, PFE & XRAY Buy Opportunities》
$PFE看涨
AI 摘要 · 辉瑞(PFE)值得买入:下行风险受6%股息率和已计入的坏消息保护,上行空间来自肿瘤学和GLP-1管线。

我喜欢它,因为它太不受青睐,你甚至送都送不掉这只股票。在等待他们扭转局面的同时,你能获得 6% 的股息收益率。他们曾因疫情获得意外之财。他们用这笔钱收购了 CGEN,430 亿美元。

这将每年带来 100 亿美元的收入。他们削减了 72 亿美元的成本。人们担心他们一些主要药物失去独家经营权。这低于预期。而且他们有一种 GLP1 药物,与 Metera 一起推出,2728 年,这是一种每月一次的 GLP,可以以药丸和皮下注射的形式服用。

所以也许他们会迟到,也许它会具有革命性。我们不知道。但与此同时,成本已经削减。肿瘤学特许经营管线强劲。所有坏消息都已反映在价格中。我早年在这个行业学到,如果下行风险得到保护,上行空间会自行解决。

如果我获得 6% 的报酬来等待这只股票随时间恢复,那是好事,不是坏事。

I love it because it's so out of favor you can't give the stock away. Um you're getting a 6% dividend yield while you wait for them to turn the boat. They had a COVID windfall.

They used the money to buy CGEN 43 billion. That's going to do10 billion dollars a year. They cut 7.2 billion in cost. People are afraid of the loss of exclusivity from some of their major drugs.

It's lower than expected. And they have a GLP1 with the Metera coming out uh 2728, which is once a month GLP uh which you can take as a pill and subcutaneous. So maybe they'll be late to the party, maybe it'll be revolutionary.

We don't know. But in the meantime, costs are out. The oncology franchise pipeline is robust. All the bad news is priced in. You you got you're you know, I learned early on in this business, if your downside is protected, your upside will take care of itself.

And if I'm paid 6% to wait while this thing, you know, uh recovers over time. That's a good thing, not a bad thing.

Dividendology发布 2026-08-11
《Insiders Buying Pfizer Stock at a 52 Week Low! | Pfizer (PFE) Stock Analysis! |》
$PFE看跌
AI 摘要 · 辉瑞(PFE)目前并非好的买入选择;由于派息超过自由现金流,股息可持续性存疑,且尽管有内部人士买入,DCF分析仍显示显著下行空间。

一只高收益股息股刚刚出现了内部人士一年半以来的首次买入,我不会让你久等,现在就告诉你这只股票是什么。它就是辉瑞。

A high-yield dividend stock just saw insiders start buying for the first time in over a year and a half, and I'm not going to make you wait to reveal the stock. It's Pfizer.

辉瑞是一只过去几年表现非常挣扎的股票。我已经关注它一段时间了,但按当前价格计算,它的股息率约为6.4%。然而,至少在过去几年里,我已经指出了我对这家公司的一些主要担忧,你可以看到股价已经大幅下跌。

如果我们看过去5年,股价下跌了41%,仅在过去6个月就下跌了近42%,下跌了2.61%。

And Pfizer is a stock that's really struggled over the last few years. I've been covering it for a while now, but it's yielding around 6.4% at its current prices. However, I've pointed out some major concerns I have with the company at least over the last few years, and you can see the share price has been decimated.

If we look in the last 5 years, the stock is down by 41 nearly 42% in the last 6 months alone, down by 2.61%.

已经是最早的记录
其他股票的全部观点条目
把 $PFE 加入我的股票30 天完整试用
开始试用